Hyderabad doctor brings down rare disease drug cost from ₹9 crore to ₹2.5 lakh; seven children to get free treatment
The Hindu — Health · 19 Nov 2026 · 4 min read
HYDERABAD Imagine having a medicine that could help manage your child’s rare genetic condition, but being unable to afford it because a year’s treatment costs as much as ₹9 crore.
For seven families in India, that situation could soon change.
Seven children diagnosed with Allan-Herndon-Dudley syndrome (AHDS), a rare genetic disorder, are set to receive a year’s supply of the medicine tiratricol free of cost on November 30, following an initiative led by Hyderabad-based paediatrician Dr.
Sivaranjani Santosh and Access to Medicines India. https://www.thehindu.com/news/cities/Hyderabad/ors-labelling-row-hyderabad-paediatrician-sivaranjani-santosh-refuses-to-back-down-amid-pressure/article70810716.ece The development is significant not just because the families will receive the medicine without paying for it, but also because its cost has been brought down through pharmaceutical compounding in the Netherlands.
While the commercial version of the drug costs approximately ₹4.68 crore to ₹9 crore per child annually, the compounded formulation is estimated to cost just ₹2.5 lakh per child for a year.
The medicine has been prepared by Transvaal Pharmacy in The Hague, Netherlands, with support from the Netherlands-based Pharmaceutical Accountability Foundation (PAF).
The first batch will be handed over to the parents of the seven children along with the necessary documentation and individual import permissions.
The families have secured approvals for one year of treatment.
As the compounded medicine has a shelf life of six months, it will be imported in two batches.
How did a ₹9-crore treatment become available for ₹2.5 lakh?
The initiative began after Arav, a child under the care of Dr.
Sivaranjani, was diagnosed with AHDS, also known as MCT8 deficiency.
The condition is caused by mutations affecting the MCT8 gene, which plays an important role in transporting thyroid hormones into brain cells.
Tiratricol, also known as TRIAC, acts on thyroid hormone receptors and may help overcome some effects of the deficiency.
It also helps minimise complications associated with peripheral thyrotoxicosis.
Although the medicine was available in Europe, its commercial price put it beyond the reach of most Indian families.
Arav’s mother, Pavitra Sirolkar, had to arrange approximately ₹12 lakh to ₹13 lakh for just one month’s supply of the medicine from Germany.
Dr Sivaranjani initially approached paediatricians, endocrinologists and paediatric neurologists to explore ways of procuring the drug.
Doctors at Christian Medical College (CMC), Vellore, where five other children with the same condition had been identified, were also approached.
Who decides the cost of medicines in India?
Who decides the cost of medicines in India?
India’s separation of medicine licensing under CDSCO and pricing under NPPA presents a policy challenge.
Stronger coordination,supported by pharmaceutical, clinical and health-economic expertise, could bridge this gap Who decides the cost of medicines in India? storyline 1 Attempts to obtain the medicine through pharmaceutical company Egetis Therapeutics and its compassionate-use programme did not succeed.
The situation eventually prompted Dr Sivaranjani to take the issue to social media.
On September 7, she posted an appeal seeking help for the family and urged people to tag the Prime Minister, Union Health Minister and other government representatives.
The appeal gained attention, bringing it to the notice of PAF.
The foundation subsequently explored the possibility of preparing the medicine through pharmaceutical compounding using the active pharmaceutical ingredient.
Transvaal Pharmacy conducted test batches and developed a formulation for the seven children.
The initial group included Arav and five children receiving treatment at CMC Vellore.
A seventh child, aged one year, was identified after his father contacted Dr Sivaranjani following her social media appeal. https://www.thehindu.com/sci-tech/science/rare-disease-drugs-could-become-indias-next-pharma-frontier/article71518560.ece Who is funding the treatment?
According to PAF, the total cost of providing one year’s treatment to all seven children is €14,200, approximately ₹15.08 lakh.
Of this, Dr Sivaranjani raised approximately ₹6.09 lakh in India, while PAF undertook to raise the remaining €8,600, approximately ₹9.13 lakh, in the Netherlands.
The medicine will be provided to all seven families free of cost.
Why rare-disease drugs could become India’s next pharma frontier Why rare-disease drugs could become India’s next pharma frontier Since India has already shown the world how to make drugs affordable, the next challenge is to show the world how to make rare-disease drugs accessible; with a streamlined regulatory pathway, appropriate financial incentives, and government procurement, India could build a globally competitive rare-disease pharmaceutical sector Why rare-disease drugs could become India’s next pharma frontier storyline 1 Will the medicine become available in India?
While the November 30 handover addresses the immediate treatment requirements of the seven children, Dr Sivaranjani believes that importing the medicine cannot be a permanent solution.
She plans to approach the Union government and work with Access to Medicines India and other organisations to explore the possibility of getting the medicine compounded in India and making it accessible to more children. “How can a medicine be available in the world but not be available for our children?
We should get the medicine compounded in India and make it available for all the children with this condition,” she said.
Related articles
India · The Hindu — Health · 18 hours agoWhy data interoperability is critical to the future of hospital care
The future of critical care will be defined by how effectively the information is connected, interpreted and applied
Read full article
India · The Hindu — Health · 23 hours agoSellas’ cancer vaccine extends survival in blood cancer trial, company says
The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow
Read full article
India · The Hindu — Health · 1 day agoIndia missed its 2025 TB elimination target. What does the WHO report show?
The WHO’s Global Tuberculosis Report 2026 has withheld India’s 2025 incidence estimate pending an assessment of new surveillance data. What does the report reveal…
Read full article